TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX
TG Therapeutics shares fell 6.6% on Friday to close at $28.47, down $2.03, as the biotech stock swung between $28.21 and $30.83 on about 3.3 million shares.
TG Therapeutics (NASDAQ:TGTX) falls as BRIUMVI revenue increase outweighed by rising costs
TG Therapeutics Inc shares fell in early trading in New York on Monday, as stronger BRIUMVI sales did not offset a significant earnings shortfall and broader spending outlook. Evercore ISI analyst Michael DiFiore noted that analysts were “underestimating operating expenses.”
TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next
TG Therapeutics shares fell about 7% on Friday, reversing an early rise and leaving the biotech near its session low. The stock was down 7% at $28.35 by 3:55 p.m. EST after opening at $30.69 and sliding as low as $28.215. It hit $30.83 earlier in the session.
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseasesgurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S.gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers.
TechStock² Updates
